A major international R&D company, responsible for multiple blockbuster molecules where US rights had been out licensed to top pharma companies, was looking to launch its first fully owned, fully commercialized asset into the US market.
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down in response to changing launch timelines and to balance short- and long-term objectives. With a heavy emphasis on market development, we empowered the client to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
Goals Achieved
Challenge
Challenge
+
+
Mission Accomplished
A small public specialty pharmaceutical company wanted to expand its footprint of commercial operations and launch into key European markets.
+
Goals
Goals
We proposed a joint development model with a shared purpose and goals for accelerating development of a key product. Our team – consisting of oncology and operational experts as well as product development strategists -- were fully aligned within the company’s own product development team, creating truly seamless collaboration as we assumed responsibility for delivering their phase I/II clinical studies. This was during the pandemic, and we encouraged the company to move forward even though other companies were choosing to hold back. High levels of recruitment showed how the company became a solution for patients when other sponsors were not. By leveraging Syneos Health strengths to accelerate clinical development and support patients while building a global oncology presence, the company achieved fast track FDA approval and orphan drug designation within two years of our collaboration.
+
Challenge Accepted
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for its first commercial launch.
+
Mission
Mission
We worked with the company to evolve the traditional outsourcing model, assembling teams able to assess and plan for a large number of assets simultaneously. These strong clinical development teams were led by Syneos Health asset strategists – exceptional individuals with a wealth of experience across the product development continuum who understood the company’s mission and culture. The teams conducted expert market analysis and the early-stage clinical trials needed for efficient go/no-go decision-making – thus helping the company conserve its capital for other investments -- and then optimized product development plans for the most promising assets moving forward. These asset teams included Syneos Health operational and therapeutic experts so that there was a seamless transition from asset planning to Phase I-III study execution.
+
+
+
Challenge
Challenge
Goal Achieved
+
+
Goals
Goals
We helped build a European commercial capability via a comprehensive commercialization partnership, introducing a Commercial Leadership function to support the design and execution of the overall launch plan and integrate other services. We were able to scale quickly and establish commercial operations, designed European launch plan, forecast and launched within three months in one EU country, with a subsequent sequenced launch through Europe, despite ambiguities of COVID-19.
+
+
Mission
Mission
A small biotech company with a large portfolio of assets and a small number of staff. They wanted to continue maintaining a small staff footprint and low fixed costs while they made go/no-go product development decisions for a group of promising, recently acquired assets.
+
Mission
Mission
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down to respond to changing launch timelines and to balance short- and long-term financial objectives. With a heavy emphasis on market development, we empowered the customer to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
+
+
A major international R&D company, responsible for multiple blockbuster molecules where US rights had been out licensed to top pharma companies, was looking to launch its first fully owned, fully commercialized asset into the US market.
A major international R&D company, responsible for multiple blockbuster molecules where US rights had been out licensed to top pharma companies, was looking to launch its first fully owned, fully commercialized asset into the US market.
A small public specialty pharmaceutical company wanted to expand its footprint of commercial operations and launch into key European markets.
A small public specialty pharmaceutical company wanted to expand its footprint of commercial operations and launch into key European markets.
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for its first commercial launch.
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for its first commercial launch.
Goals Achieved
Goals Achieved
Goals Achieved
Goals Achieved
Goals Achieved
Goals Achieved
Goals Achieved
Mission Accomplished
Mission Accomplished
Mission Accomplished
Mission Accomplished
Mission Accomplished
Challenge Accepted
Challenge Accepted
Challenge Accepted
Challenge Accepted
Challenge Accepted
In 12 weeks, we provided a full virtual infrastructure that included Field Teams, MSLs, Access Teams, Marketplace and Access/Pricing Consulting, Advertising, Public Relations and Medical Communications, increasing operational efficiencies through integrated Communications teams to reduce duplication in effort across promotional channels and recruiting, training and deploying sales reps, achieving an annual run rate of >$200 million.
Mission Accomplished
Challenge Accepted
Challenge Accepted
Challenge Accepted
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for its first commercial launch.
+
Mission Accomplished
Mission Accomplished
A small public specialty pharmaceutical company wanted to expand its footprint of commercial operations and launch into key European markets.
+
Challenge Accepted
Challenge Accepted
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for its first commercial launch.
+
Goals Achieved
Goals Achieved
A major international R&D company, responsible
for multiple blockbuster molecules where US rights had been out licensed to top pharma companies, was looking to launch its first fully owned, fully commercialized asset into the US market.
+
Mission Accomplished
Mission Accomplished
A small public specialty pharmaceutical company wanted to expand its footprint of commercial operations and launch into key European markets.
+
Goals Achieved
Goals Achieved
A major international R&D company, responsible
for multiple blockbuster molecules where US rights had been out licensed to top pharma companies, was looking to launch its first fully owned, fully commercialized asset into the US market.
+